Detection of HIV-1 Tat in the serum of HIV-1—infected patients
HIV-1+ patients . | Tat, ng/mL* . |
|---|---|
| 1 | 300 |
| 2 | 400 |
| 3 | 400 |
| 4 | 500 |
| 5 | 550 |
| 6 | 300 |
| 7 | 150 |
| 8 | 400 |
| 9 | 150 |
| 10 | < 50 |
| 11 | 250 |
| 12 | 250 |
| 13 | 250 |
| 14 | < 50 |
| 15 | 400 |
| 16 | 550 |
| 17 | 450 |
| 18 | 450 |
| 19 | 150 |
| 20 | 250 |
| 21 | 300 |
| 22 | 350 |
| 23 | < 50 |
| 24 | 400 |
| 25 | < 50 |
| 26 | 200 |
| 27 | 250 |
| 28 | 550 |
| HIV-1- HBV+/HCV+ patients | |
| 1 | ND |
| 2 | ND |
| 3 | < 10 |
| 4 | < 10 |
| 5 | ND |
| 6 | ND |
| 7 | < 10 |
| 8 | ND |
| 9 | ND |
| 10 | < 10 |
| Healthy donors | |
| H1 | ND |
| H2 | ND |
| H3 | ND |
| H4 | ND |
| H5 | < 10 |
| H6 | < 10 |
| H7 | ND |
| H8 | < 10 |
| H9 | ND |
| H10 | ND |
| H11 | ND |
| H12 | < 10 |
| H13 | ND |
| H14 | ND |
| H15 | ND |
HIV-1+ patients . | Tat, ng/mL* . |
|---|---|
| 1 | 300 |
| 2 | 400 |
| 3 | 400 |
| 4 | 500 |
| 5 | 550 |
| 6 | 300 |
| 7 | 150 |
| 8 | 400 |
| 9 | 150 |
| 10 | < 50 |
| 11 | 250 |
| 12 | 250 |
| 13 | 250 |
| 14 | < 50 |
| 15 | 400 |
| 16 | 550 |
| 17 | 450 |
| 18 | 450 |
| 19 | 150 |
| 20 | 250 |
| 21 | 300 |
| 22 | 350 |
| 23 | < 50 |
| 24 | 400 |
| 25 | < 50 |
| 26 | 200 |
| 27 | 250 |
| 28 | 550 |
| HIV-1- HBV+/HCV+ patients | |
| 1 | ND |
| 2 | ND |
| 3 | < 10 |
| 4 | < 10 |
| 5 | ND |
| 6 | ND |
| 7 | < 10 |
| 8 | ND |
| 9 | ND |
| 10 | < 10 |
| Healthy donors | |
| H1 | ND |
| H2 | ND |
| H3 | ND |
| H4 | ND |
| H5 | < 10 |
| H6 | < 10 |
| H7 | ND |
| H8 | < 10 |
| H9 | ND |
| H10 | ND |
| H11 | ND |
| H12 | < 10 |
| H13 | ND |
| H14 | ND |
| H15 | ND |
Tat measurements in the sera of HIV-1-infected patients, patients with HBV/HCV infection, and healthy donors were performed using ELISA with a rabbit anti-Tat antiserum (10 μg/mL) as capture antibody and a biotinylated rabbit anti-Tat antiserum (1 μg/mL) as detection antibody, followed by Av-HRP (1:2000) and by the specific substrate. Results (ng/mL) referred to synthetic Tat (Tecnogen) used as standard.
ND indicates not detectable.